Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | CDC25B | P30305 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28073989 | 1.00 | PTPN1 (0.62) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL8840053 | 0.90 | PTPN1 (0.53) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL28515929 | 0.89 | PTPN1 (0.62) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL27649591 | 0.89 | PTPN1 (0.62) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL27370153 | 0.85 | PTPN1 (0.59) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL27369404 | 0.85 | PTPN1 (0.59) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL27240806 | 0.85 | PTPN1 (0.59) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL5720401 | 0.85 | PTPN1 (0.59) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL27357388 | 0.85 | PTPN1 (0.59) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL6242035 | 0.83 | PTPN1 (0.56) | PTPN1LMNAPTGS1PDE4ASNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411052-B1 | CARRIER COMPRISING A VITAMIN E DERIVATIVE AND ANNEXIN V | UCL BUSINESS LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| US-10470986-B2 | Resorcinol compounds for dermatological use | CONOPCO, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| EP-2964182-B1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER PLC A COMPANY REGISTERED IN ENGLAND AND WALES UNDER COMPANY NO 41424 OF (GB) | 2018-02-14 | — | — | EP | disclosed |
| US-9545392-B2 | Carrier comprising a vitamin E derivative | UCL BUSINESS PLC (GB) | 2017-01-17 | — | — | US | disclosed |
| US-9539203-B2 | Pharmaceutical composition comprising a Vitamin E derivative and a cell death marker | UCL BUSINESS PLC (GB) | 2017-01-10 | — | — | US | disclosed |
| EP-2234596-B1 | CARRIER | UCL BUSINESS PLC (GB) | 2016-10-19 | — | — | EP | disclosed |
| EP-2964182-A2 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | Unilever PLC, a company registered in England and Wales under company no. 41424 of (GB) | 2016-01-13 | — | — | EP | disclosed |
| US-20160000669-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | CONOPCO, INC., D/B/A UNILEVER (US) | 2016-01-07 | — | — | US | disclosed |
| WO-2015183970-A1 | THERAPEUTIC COMPOSITIONS INCLUDING FLAVONOID AND USES THEREOF | STEALTH PEPTIDES INTERNATIONAL, INC. (MC) | 2015-12-03 | — | — | WO | disclosed |
| WO-2015183984-A2 | THERAPEUTIC COMPOSITIONS INCLUDING TOCOPHEROL AND USES THEREOF | STEALTH PEPTIDES INTERNATIONAL, INC. (MC) | 2015-12-03 | — | — | WO | disclosed |
| EP-1418904-A2 | TOCOPHEROL ENRICHED COMPOSITIONS AND AMELIORATION OF INFLAMMATORY SYMPTOMS | Galileo Laboratories, Inc. (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20040048919-A1 | Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects | ALLOY VENTURES, INC. | 2004-03-11 | — | — | US | disclosed |
| WO-2004004638-A2 | COMPOSITIONS AND METHODS FOR REDUCTION OF INFLAMMATORY SYMPTOMS AND/OR BIOMARKERS IN FEMALE SUBJECTS | GALILEO PHARMACEUTICALS, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20030144219-A1 | Formulations and methods for treatment or amelioration of inflammatory conditions | JOHNSON & JOHNSON CONSUMER INC. | 2003-07-31 | — | — | US | disclosed |
| WO-2003043570-A2 | FORMULATIONS AND METHODS FOR TREATMENT OR AMELIORATION OF INFLAMMATORY CONDITIONS | GALILEO LABORATORIES, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| US-20030100603-A1 | Tocopherol enriched compositions and amelioration of inflammatory symptoms | JOHNSON & JOHNSON CONSUMER INC. | 2003-05-29 | — | — | US | disclosed |
| US-6528042-B1 | Non-naturally-occurring compositions for use in amelioration of disruption of energy metabolism secondary to stress are described. These compositions comprise a flavonoid or derivative thereof and a synergist. Synergists include such as | GALILEO LABORATORIES, INC. | 2003-03-04 | — | — | US | disclosed |
| WO-2003015494-A2 | TOCOPHEROL ENRICHED COMPOSITIONS AND AMELIORATION OF INFLAMMATORY SYMPTOMS | GALILEO PHARMACEUTICALS, INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| US-20030022818-A1 | Formulations of tocopherols and methods of making and using them | ALLOY VENTURES, INC. | 2003-01-30 | — | — | US | disclosed |
| US-6426362-B1 | RELIEVING CELL STRESS; SYNERGISTIC MIXTURE WITH FLAVONOIDS, TRANSFERRIN | GALILEO LABORATORIES, INC. | 2002-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144219-A1 | Formulations and methods for treatment or amelioration of inflammatory conditions | ALOX15B, ALOX5, ALOX12 | PTPN1 2715/4885LMNA 834/4885PTGS1 37/4885 |
| US-20040048919-A1 | Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects | PGR, PTGES3, PGRMC1 | PTPN1 4508/4885LMNA 1046/4885PTGS1 39/4885 |
| US-20160000669-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | NQO1, RBP4, KEAP1 | PTPN1 3204/4885LMNA 338/4885PTGS1 1766/4885 |
| US-10470986-B2 | Resorcinol compounds for dermatological use | NQO1, RBP4, KEAP1 | PTPN1 3204/4885LMNA 338/4885PTGS1 1766/4885 |
| US-20030100603-A1 | Tocopherol enriched compositions and amelioration of inflammatory symptoms | TTPA, TNNT2, GSR | PTPN1 2471/4885LMNA 1011/4885PTGS1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.